These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9464661)

  • 1. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.
    Gifford AN; Tang Y; Gatley SJ; Volkow ND; Lan R; Makriyannis A
    Neurosci Lett; 1997 Nov; 238(1-2):84-6. PubMed ID: 9464661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
    Gifford AN; Ashby CR
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.
    Gessa GL; Mascia MS; Casu MA; Carta G
    Eur J Pharmacol; 1997 May; 327(1):R1-2. PubMed ID: 9185841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.
    Gifford AN; Samiian L; Gatley SJ; Ashby CR
    Eur J Pharmacol; 1997 Apr; 324(2-3):187-92. PubMed ID: 9145770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large receptor reserve for cannabinoid actions in the central nervous system.
    Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
    J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.
    Kathmann M; Weber B; Schlicker E
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):50-6. PubMed ID: 11191836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes.
    Gifford AN; Bruneus M; Gatley SJ; Volkow ND
    Br J Pharmacol; 2000 Oct; 131(3):645-50. PubMed ID: 11015319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
    Gessa GL; Casu MA; Carta G; Mascia MS
    Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
    Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
    Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR; Koek W
    Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
    Pan X; Ikeda SR; Lewis DL
    Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human.
    Martin RS; Luong LA; Welsh NJ; Eglen RM; Martin GR; MacLennan SJ
    Br J Pharmacol; 2000 Apr; 129(8):1707-15. PubMed ID: 10780977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
    Kathmann M; Bauer U; Schlicker E; Göthert M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice.
    Kathmann M; Weber B; Zimmer A; Schlicker E
    Br J Pharmacol; 2001 Mar; 132(6):1169-73. PubMed ID: 11250865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
    Acquas E; Pisanu A; Marrocu P; Di Chiara G
    Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.
    Maneuf YP; Brotchie JM
    Br J Pharmacol; 1997 Apr; 120(8):1397-8. PubMed ID: 9113356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices.
    Ameri A; Simmet T
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):265-72. PubMed ID: 10731038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse.
    Mancinelli R; Fabrizi A; Del Monaco S; Azzena GB; Vargiu R; Colombo GC; Gessa GL
    Life Sci; 2001 May; 69(1):101-11. PubMed ID: 11411800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex.
    Page ME; Oropeza VC; Van Bockstaele EJ
    Neurosci Lett; 2008 Jan; 431(1):1-5. PubMed ID: 18055114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.